Sorafenib for the treatment of breast cancer.

about

RET rearrangements are actionable alterations in breast cancer

P2860

Q59136613-BF5C5EAB-4D72-4375-A0D7-827F8647BBC0

P2860

Sorafenib for the treatment of breast cancer.

Item

http://www.wikidata.org/entity/Q38881805

description

2017 nî lūn-bûn

@nan

2017年の論文

@ja

2017年論文

@yue

2017年論文

@zh-hant

2017年論文

@zh-hk

2017年論文

@zh-mo

2017年論文

@zh-tw

2017年论文

@wuu

2017年论文

@zh

2017年论文

@zh-cn

name

Sorafenib for the treatment of breast cancer.

@en

type

Item

label

Sorafenib for the treatment of breast cancer.

@en

prefLabel

Sorafenib for the treatment of breast cancer.

@en

P1476

Sorafenib for the treatment of breast cancer.

@en

P2093

Alberto Farolfi

http://www.w3.org/2001/XMLSchema#string

Alessio Schirone

http://www.w3.org/2001/XMLSchema#string

Andrea Rocca

http://www.w3.org/2001/XMLSchema#string

Anna Fedeli

http://www.w3.org/2001/XMLSchema#string

Caterina Donati

http://www.w3.org/2001/XMLSchema#string

Dino Amadori

http://www.w3.org/2001/XMLSchema#string

Giuseppe Bronte

http://www.w3.org/2001/XMLSchema#string

Lorenzo Cecconetto

http://www.w3.org/2001/XMLSchema#string

Patrizia Serra

http://www.w3.org/2001/XMLSchema#string

Roberta Maltoni

http://www.w3.org/2001/XMLSchema#string

P2860

Anti-vascular endothelial growth factor therapy in breast cancer

Tailoring therapies--improving the management of early breast cancer: St Gallen International Expert Consensus on the Primary Therapy of Early Breast Cancer 2015

Sorafenib: a review of its use in advanced hepatocellular carcinoma

Paclitaxel plus bevacizumab versus paclitaxel alone for metastatic breast cancer

BAY 43-9006 exhibits broad spectrum oral antitumor activity and targets the RAF/MEK/ERK pathway and receptor tyrosine kinases involved in tumor progression and angiogenesis

ESO-ESMO 2nd international consensus guidelines for advanced breast cancer (ABC2)†

First-line bevacizumab in combination with chemotherapy for HER2-negative metastatic breast cancer: pooled and subgroup analyses of data from 2447 patients.

Global surveillance of cancer survival 1995-2009: analysis of individual data for 25,676,887 patients from 279 population-based registries in 67 countries (CONCORD-2).

Phase III randomized trial of sunitinib versus capecitabine in patients with previously treated HER2-negative advanced breast cancer.

Phase III study of bevacizumab plus docetaxel compared with placebo plus docetaxel for the first-line treatment of human epidermal growth factor receptor 2-negative metastatic breast cancer.

P304

621-630

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1080/14656566.2017.1309024

http://www.w3.org/2001/XMLSchema#string

P407

English

P433

http://www.w3.org/2001/XMLSchema#string

P478

http://www.w3.org/2001/XMLSchema#string

P50

Daniele Andreis

P577

2017-03-24T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

28335647

http://www.w3.org/2001/XMLSchema#string

Sorafenib for the treatment of breast cancer.

about

P2860

P2860

Sorafenib for the treatment of breast cancer.

description

name

type

label

prefLabel

P1433

P1476

P2093

P2860

P304

P31

P356

P407

P433

P478

P50

P577

P698

P356

P1433

P1476

P2093

P2860

P304

P31

P356

P407

P433

P478

P50

P577

P698